NASDAQ · CYTK
Healthcare · Biotechnology
$62.99
Down-$0.32 (-0.51%)
Updated Nov 2, 2026, 7:01 AM
SID Score
4.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance · CYTK
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
CYTK closed at $62.99 after 20 trading sessions, up 0.46% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $63.44 | $64.50 | $62.55 | $62.99 | 1.26M |
| Oct 29, 2026 | $62.08 | $63.95 | $61.54 | $63.31 | 1.43M |
| Oct 28, 2026 | $60.86 | $61.39 | $60.145 | $61.28 | 1.27M |
| Oct 27, 2026 | $60.68 | $61.83 | $60.47 | $61.52 | 1.15M |
| Oct 26, 2026 | $61.45 | $61.89 | $60.475 | $60.73 | 783.24K |
| Oct 23, 2026 | $62.01 | $62.44 | $60.8903 | $61.23 | 985.63K |
| Oct 22, 2026 | $63.01 | $64.07 | $61.94 | $62.33 | 2.06M |
| Oct 21, 2026 | $64.30 | $64.78 | $62.4583 | $62.86 | 1.08M |
| Oct 20, 2026 | $63.13 | $64.755 | $62.88 | $63.95 | 1.05M |
| Oct 19, 2026 | $62.06 | $63.605 | $61.84 | $62.65 | 1.91M |
| Oct 16, 2026 | $63.90 | $63.90 | $61.685 | $61.95 | 1.2M |
| Oct 15, 2026 | $64.81 | $65.57 | $63.81 | $63.92 | 1.67M |
| Oct 14, 2026 | $61.62 | $64.01 | $60.99 | $63.43 | 2.1M |
| Oct 13, 2026 | $62.32 | $63.05 | $61.50 | $61.62 | 1.94M |
| Oct 12, 2026 | $62.48 | $63.50 | $62.13 | $62.79 | 1.25M |
| Oct 9, 2026 | $61.87 | $63.03 | $61.59 | $62.91 | 1.12M |
| Oct 8, 2026 | $60.31 | $62.79 | $59.785 | $62.01 | 2.59M |
| Oct 7, 2026 | $61.085 | $62.05 | $60.1546 | $61.12 | 2.4M |
| Oct 6, 2026 | $62.20 | $62.525 | $60.68 | $61.35 | 3.23M |
| Oct 5, 2026 | $65.60 | $65.755 | $62.19 | $62.70 | 3.23M |
The latest Smart Investors Daily articles mentioning CYTK.
Company
Market Activity
Research & News
CYTK research
Company profile and research snapshot.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 16, 2026 | William Blair | Outperform | — |
| Oct 8, 2026 | RBC Capital | Outperform | — |
| Aug 31, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2026 | JP Morgan | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 29, 2026
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 28, 2026
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SeekingAlpha · Oct 26, 2026
The Baron Health Care Fund Q3 2026 report highlights key contributors and detractors from portfolio performance. Read the full analysis for more details.
Yahoo · Oct 21, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of C
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CYTK.
